New targeted drug shows promise for hard-to-treat breast cancers
NCT ID NCT06840483
First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 26 times
Summary
This study tests an experimental drug, zelenectide pevedotin, in people with advanced breast cancer that has a specific genetic change called NECTIN4 amplification. The trial includes two groups: one with hormone receptor-positive/HER2-negative cancer and another with triple-negative breast cancer. The main goal is to see if the drug can shrink tumors, while also checking for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinica Oncologica-Azienda Ospedaliero Universitaria delle Marche
Ancona, 60126, Italy
-
Compass Oncology - Rose Quarter Cancer Center
Portland, Oregon, 97227, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke Cancer Institute
Durham, North Carolina, 27710, United States
-
Hospital Beata Maria Ana
Madrid, 28007, Spain
-
Hospital Quironsalud Barcelona
Barcelona, 08023, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Istituto Europeo di Oncologia
Milan, 20141, Italy
-
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRCCS IRST
Meldola, Forli/Cesena, 47014, Italy
-
Memorial Sloan Kettering Cancer Center - Main Campus
New York, New York, 10065, United States
-
Oncopole Claudius Regaud
Toulouse, 31059, France
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (SKCCC)
Baltimore, Maryland, 21287, United States
-
Siteman Cancer Center
St Louis, Missouri, 63108, United States
-
Texas Oncology San Antonio
San Antonio, Texas, 78240, United States
-
The Royal Marsden NHS Foundation Trust
London, SW3 6JJ, United Kingdom
-
UZ Leuven
Leuven, 3000, Belgium
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.